Cognitive Remediation of Cognitive Control in Late-Life Depression
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS)
研究概览
简要总结
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants. The investigators are also interested in whether participating in the treatment will result in changes to brain activity measured with magnetic resonance imaging (MRI).
详细描述
Major depression in the elderly is both challenging to treat and detrimental to the cognitive functioning of patients. Major depression increases the probability of a later dementia diagnosis. By targeting cognitive processes in treatment, the investigators hope to both find a more effective means to manage major depression in older adults, but also demonstrate how top-down processes (e.g., Executive Control Network) may be driving depression and cognitive decline in older adults.
The investigators are recruiting older adults with and without mild cognitive impairment. All subjects must have at least mild depressive symptoms to be eligible to participate. Subjects will be randomly assigned to one of two different interventions.
Results of this study will help the investigators understand the mechanisms that contribute to depressed mood and cognitive change in older adults with late life depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ability to read and write in English
- •current major or mild depression despite ongoing treatment
- •under the care of a physician who prescribes medication for depression
- •currently treated with an antidepressant for at least 8 weeks
排除标准
- •psychosis
- •other psychiatric disorders (except personality & generalized anxiety disorders)
- •substance use disorders in the prior year
- •clinical diagnosis of dementia
- •neurological disorders (e.g., stroke, epilepsy, brain injury with loss of consciousness > 30 minutes, brain tumors, demyelinating diseases)
- •corrected visual acuity < 20/70 or color blindness
结局指标
主要结局
Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS)
时间窗: Pre-treatment and six weeks later when treatment has ended
depression rating scale
Change in attention / cognitive flexibility as measured by the Trail Making Part B test
时间窗: Pre-treatment and six weeks later when treatment has ended
time to complete alpha-numeric sequencing
次要结局
- Change in problem solving/speed/spatial memory as measured with the NIH Toolbox fluid composite scales(Pre-treatment and six weeks later when treatment has ended)
- Change in self-reported depressive symptoms measured with the Carroll Depression Rating Scale(Pre-treatment and six weeks later when treatment has ended)
- Change in verbal learning as measured with the California Verbal Learning Test (CVLT) Total Learning(Pre-treatment and six weeks later when treatment has ended)
- Change in attention processing speed as measured with the Flanker Test of Response Inhibition from the NIH Cognitive Toolbox(Pre-treatment and six weeks later when treatment has ended)
研究者
Kevin Manning
Associate Professor
UConn Health